Do analysts rate SILO or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer XRTX or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to XRTX or EVFM?

In the previous week, XORTX Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for XORTX Therapeutics and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.67 beat XORTX Therapeutics' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XORTX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evofem Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EVFM or REVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to SXTP or EVFM?

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 1 articles in the media. Evofem Biosciences' average media sentiment score of 0.67 beat 60 Degrees Pharmaceuticals' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evofem Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SPRC or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, SPRC or EVFM?

Evofem Biosciences has higher revenue and earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.40 -$12.18M N/A N/A Evofem Biosciences $11.39M 0.09 $52.98M -$0.13 N/A

Does the media favor SPRC or EVFM?

In the previous week, SciSparc had 4 more articles in the media than Evofem Biosciences. MarketBeat recorded 5 mentions for SciSparc and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.67 beat SciSparc's score of 0.28 indicating that Evofem Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evofem Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evofem Biosciences (EVFM) Competitors

$0.0075 0.00 (-6.25%)

As of 09/3/2026 03:31 PM Eastern

Compare

EVFM vs. SILO, XRTX, REVB, SXTP, and SPRC

Should you buy Evofem Biosciences stock or one of its competitors? Evofem Biosciences's main competitors and comparable companies include Silo Pharma (SILO), XORTX Therapeutics (XRTX), Revelation Biosciences (REVB), 60 Degrees Pharmaceuticals (SXTP), and SciSparc (SPRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Evofem Biosciences compare to Silo Pharma?

Silo Pharma (NASDAQ:SILO) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Evofem Biosciences has a net margin of -46.42% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Silo Pharma has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.31, indicating that its share price is 231% less volatile than the broader market.

In the previous week, Evofem Biosciences had 1 more articles in the media than Silo Pharma. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Silo Pharma. Evofem Biosciences' average media sentiment score of 0.67 beat Silo Pharma's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Silo Pharma	Neutral
Evofem Biosciences	Positive

Evofem Biosciences has higher revenue and earnings than Silo Pharma. Silo Pharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70K	55.65	-$4.23M	-$4.36	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Evofem Biosciences beats Silo Pharma on 8 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to XORTX Therapeutics?

XORTX Therapeutics (NASDAQ:XRTX) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

XORTX Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-137.85%	-108.16%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

In the previous week, XORTX Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for XORTX Therapeutics and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.67 beat XORTX Therapeutics' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XORTX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evofem Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Evofem Biosciences has higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

XORTX Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.31, suggesting that its share price is 231% less volatile than the broader market.

Summary

Evofem Biosciences beats XORTX Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to Revelation Biosciences?

Evofem Biosciences (NASDAQ:EVFM) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Evofem Biosciences has a beta of -1.31, meaning that its share price is 231% less volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market.

Evofem Biosciences has higher revenue and earnings than Revelation Biosciences. Revelation Biosciences is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Evofem Biosciences had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Revelation Biosciences. Evofem Biosciences' average media sentiment score of 0.67 beat Revelation Biosciences' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Evofem Biosciences	Positive
Revelation Biosciences	Neutral

Revelation Biosciences has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
Revelation Biosciences	N/A	-100.19%	-82.72%

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Evofem Biosciences beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.31, meaning that its share price is 231% less volatile than the broader market.

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 1,389.09%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 1 articles in the media. Evofem Biosciences' average media sentiment score of 0.67 beat 60 Degrees Pharmaceuticals' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evofem Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evofem Biosciences has higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.32	-$7.36M	-$4.82	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Evofem Biosciences has a net margin of -46.42% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Summary

60 Degrees Pharmaceuticals beats Evofem Biosciences on 8 of the 15 factors compared between the two stocks.

How does Evofem Biosciences compare to SciSparc?

SciSparc (NASDAQ:SPRC) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, SciSparc had 4 more articles in the media than Evofem Biosciences. MarketBeat recorded 5 mentions for SciSparc and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.67 beat SciSparc's score of 0.28 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evofem Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

SciSparc has a beta of 2.81, suggesting that its stock price is 181% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.31, suggesting that its stock price is 231% less volatile than the broader market.

Evofem Biosciences has higher revenue and earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.40	-$12.18M	N/A	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A

SciSparc has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. SciSparc's return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Summary

SciSparc beats Evofem Biosciences on 9 of the 12 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVFM vs. The Competition

Export

Metric	Evofem Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$994K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.01	787.27	273.29	25.25
Price / Sales	0.09	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.00	12.33	12.92	6.14
Net Income	$52.98M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.60%	0.60%	-0.27%
1 Month Performance	N/A	6.96%	5.72%	0.68%
1 Year Performance	N/A	9.45%	25.33%	14.84%

Evofem Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVFM Evofem Biosciences	N/A	$0.01 -6.3%	N/A	-21.1%	$994K	$11.39M	N/A	120	Gap Down
SILO Silo Pharma	0.4712 of 5 stars	$2.50 -3.5%	N/A	-73.8%	$4.11M	$70K	N/A	2	Short Interest Decrease
XRTX XORTX Therapeutics	0.7919 of 5 stars	$2.22 -1.8%	N/A	-47.6%	$4.11M	N/A	N/A	N/A	Positive News
REVB Revelation Biosciences	1.0207 of 5 stars	$0.96 -4.5%	N/A	-90.8%	$3.98M	N/A	N/A	10	Gap Up
SXTP 60 Degrees Pharmaceuticals	1.8979 of 5 stars	$1.08 -4.4%	$13.85 +1,182.4%	-84.1%	$3.97M	$1.41M	N/A	3	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVFM) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evofem Biosciences (EVFM) Competitors

EVFM vs. SILO, XRTX, REVB, SXTP, and SPRC

How does Evofem Biosciences compare to Silo Pharma?

Summary

How does Evofem Biosciences compare to XORTX Therapeutics?

Summary

How does Evofem Biosciences compare to Revelation Biosciences?

Summary

How does Evofem Biosciences compare to 60 Degrees Pharmaceuticals?

Summary

How does Evofem Biosciences compare to SciSparc?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evofem Biosciences (EVFM) Competitors

EVFM vs. SILO, XRTX, REVB, SXTP, and SPRC

How does Evofem Biosciences compare to Silo Pharma?

Do insiders & institutionals believe in SILO or EVFM?

Is SILO or EVFM more profitable?

Which has more risk & volatility, SILO or EVFM?

Does the media refer more to SILO or EVFM?

Which has higher earnings and valuation, SILO or EVFM?

Do analysts rate SILO or EVFM?

Summary

How does Evofem Biosciences compare to XORTX Therapeutics?

Is XRTX or EVFM more profitable?

Does the media refer more to XRTX or EVFM?

Do analysts prefer XRTX or EVFM?

Which has stronger earnings & valuation, XRTX or EVFM?

Do insiders & institutionals have more ownership in XRTX or EVFM?

Which has more volatility & risk, XRTX or EVFM?

Summary

How does Evofem Biosciences compare to Revelation Biosciences?

Which has more risk & volatility, EVFM or REVB?

Which has better valuation and earnings, EVFM or REVB?

Do analysts rate EVFM or REVB?

Does the media favor EVFM or REVB?

Is EVFM or REVB more profitable?

Do institutionals & insiders believe in EVFM or REVB?

Summary

How does Evofem Biosciences compare to 60 Degrees Pharmaceuticals?

Which has more risk and volatility, SXTP or EVFM?

Do analysts prefer SXTP or EVFM?

Does the media refer more to SXTP or EVFM?

Which has higher earnings and valuation, SXTP or EVFM?

Do institutionals & insiders believe in SXTP or EVFM?

Is SXTP or EVFM more profitable?

Summary

How does Evofem Biosciences compare to SciSparc?

Do institutionals and insiders have more ownership in SPRC or EVFM?

Does the media favor SPRC or EVFM?

Do analysts prefer SPRC or EVFM?

Which has more volatility and risk, SPRC or EVFM?

Which has stronger valuation and earnings, SPRC or EVFM?

Is SPRC or EVFM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools